Cost-effectiveness of ligation vs. beta-blockers in the prevention of variceal bleeding

April 02, 2007

Endoscopic variceal ligation is cost-effective relative to beta-blockers for the prevention of variceal bleeding in cirrhotic patients if quality of life-years are considered. If only life-years are considered, then endoscopic variceal ligation is not cost-effective. These findings are published in the April issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., Hepatology is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

Thirty to forty percent of patients with cirrhosis have esophageal varices. Bleeding from varices occurs in almost one in three of these patients and can be fatal. Non-selective beta-adrenergic blockade has been the most widely investigated therapy to reduce the risk of variceal bleeding. Another effective alternative is endoscopic variceal ligation. The effects of both treatment options on mortality are uncertain.

Since both approaches reduce the risk of variceal bleeding, researchers led by Thomas Imperiale, MD, of Indiana University School of Medicine, sought to compare their cost-effectiveness and quality of life outcomes.

They developed a Markov decision model for patients with cirrhosis, portal hypertension, and medium-to-large esophageal varices who would be candidates for primary prophylaxis with either beta-blockade or ligation. Using a 5-year time horizon, they examined direct costs, life-years, and quality-adjusted life years.

The researchers found that when only life-years are considered, ligation is not cost-effective when compared with beta-blocker therapy. However, when both life-years and quality are considered, "the gain in effectiveness with initial ligation is "worth" the increase in cost," they report. They found that over five years, for every 1000 patients with high-risk varices, initial ligation prevents variceal bleeding in 77 persons, 65 bleeding episodes, 5 TIPS procedures, and 7 deaths, as compared with initial beta-blocker therapy.

The study did not consider severe complications from TIPS, ligation or beta-blocker therapy. It also did not examine non-adherence. If TIPS or compliance (or both) had been included in the model, ligation would have been even more cost-effective. Finally, the study did not look at the costs and effects of liver transplantation or development and management of hepatocellular carcinoma. But in spite of these limitations, it clearly showed that ligation was cost-effective based on quality-adjusted life years.

"At a $50,000 willingness to pay, ligation is not cost-effective compared to beta-blocker therapy if only the life years are considered; however, at $25,548 / QALY, ligation is cost-effective if quality-adjusted life years are considered," they conclude. "Further study is needed to determine the extent to which these findings may be affected by the use of beta-blocker co-therapy after a first bleed, an extended time horizon, and by patient-derived utilities."
-end-
Article: "Cost-Effectiveness Analysis of Variceal Ligation vs. Beta-Blockers for Primary Prevention of Variceal Bleeding." Imperiale, Thomas; Klein, Robert; Chalasani, Naga. Hepatology; April 2007; (DOI: 10.1002/hep.21605).

Wiley

Related Cirrhosis Articles from Brightsurf:

Researchers discover gene that could decrease likelihood of developing alcoholic cirrhosis
Researchers at Indiana University School of Medicine are learning more about how a person's genes play a role in the possibility they'll suffer from alcoholic cirrhosis with the discovery of a gene that could make the disease less likely.

When liver cirrhosis is deadly
A study by an international team of researchers headed by Professor Jonel Trebicka from the Frankfurt University Hospital and funded by the foundation EF Clif, has discovered which patients are particularly at risk for acute-on-chronic liver failure.

Blood tests can predict the risk of liver cirrhosis
Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease, according to a new study from Karolinska Institutet in Sweden published in the Journal of Hepatology.

Universal gut microbiome-derived signature predicts cirrhosis
UC San Diego School of Medicine researchers report that stool microbiomes of NAFLD patients are distinct enough to potentially be used to accurately predict which persons with NAFLD are at greatest risk for having cirrhosis.

Strength training benefits patients with cirrhosis
Three hours of weekly strength training combined with protein supplements leads to both bigger and stronger muscles in patients with cirrhosis.

Women are not more likely to die of cirrhosis than men, despite fewer liver transplants
Prior studies suggested women might have higher mortality of cirrhosis of the liver than men.

Movement toward a poop test for liver cirrhosis
In a study of people with nonalcoholic fatty liver disease and their twins and other close relatives, UC San Diego researchers were able to diagnose liver cirrhosis simply by analyzing a person's stool microbes.

Gum disease treatment may improve symptoms in cirrhosis patients
Routine oral care to treat gum disease (periodontitis) may play a role in reducing inflammation and toxins in the blood (endotoxemia) and improving cognitive function in people with liver cirrhosis.

Alcohol-related cirrhosis deaths skyrocket in young adults
Liver disease deaths jumped by 65 percent in the United States, from 1999-2016, disproportionately affecting adults ages 25-34.

Researchers find a promising new approach for treating liver cirrhosis
In a study in The American Journal of Pathology, investigators report that treatment with aleglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma (PPARα/γ) agonist, reduced inflammation, vasoconstriction, angiogenesis, mucosal disruption, and tumor necrosis factor (TNF)-α overproduction in cirrhotic rats with PH.

Read More: Cirrhosis News and Cirrhosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.